OVERVIEW

The Problem

When Outbreaks Move in Days - But Protection Takes Months Every year, viral outbreaks sweep through pig farms, killing millions of animals and erasing billions in profit. Vaccines can't respond fast enough - they take months to adapt while viruses mutate in weeks. By the time immunity arrives, the herd is gone.

Our Opportunity

Kermode Biotechnologies is redefining animal health with AI-engineered vaccines designed from viral antigens. Our platform creates more effective vaccines while our proprietary manufacturing approach - using stable cell lines with rapid antigen swapping and integration - allows us to adapt to viral variants in weeks instead of months. This gives farmers the protection they need, when they need it.

Why Now

1. The global livestock industry loses >$3B annually to viral disease.
2. The world has just learned how fast biologics can be built - AI and mRNA tech changed expectations forever.
3. Regulators and producers are urgently searching for faster countermeasures to protect food supply chains.

Kermode is pioneering AI-designed vaccines for animals - a paradigm shift that will define the next decade of biodefense in the swine industry.

DEEPER

Kermode Biotechnologies Inc. is transforming how we protect global food security and now is your chance to partake in a global changing effort to protect one of humanities most important commodities - PROTECTING THE PORK INDUSTRY.

By merging AI-powered vaccine design with breakthrough "dominant negative" antigens and/or MHC-based T-cell priming, we're creating effective AI-designed immunotherapies against African Swine Fever Virus, Seneca Virus A, and Swine Influenza. These DIVA-compliant solutions are designed to make next-generation swine protection accessible, scalable, and effective across global agricultural markets for generations to come.

Based in Denver, Colorado, Kermode operates from executive offices that will serve as the foundation for our planned state-of-the-art research laboratories. Our leadership team combines seasoned biotech entrepreneurship with world-renowned virological expertise, drawing talent from prestigious institutions including Cornell University, Memorial Sloan Kettering, and the NIH, as well as leading pharmaceutical companies including Boehringer Ingelheim and GlaxoSmithKline. This exceptional team has a proven track record of success, having previously developed and commercialized veterinary products that generated over $500 million in combined annual revenue.

Our pioneering singular and dual-mechanism approach to swine disease prevention is backed by $1.5+ million in funding from sophisticated agricultural investors in China and the US.

Critical Need for Advanced Vaccine Solutions in a Crisis-Driven Industry

The swine industry faces an unprecedented crisis demanding immediate innovation. Senecavirus A has exploded 300% globally since 2015, creating dangerous pathways for secondary infections that threaten herd survival. African Swine Fever Virus has caused $60 billion in global economic impact and remains an existential threat to American pork with no vaccine available. Swine Influenza Virus has generated $750 million in US losses plus thousands of human infections, with rapid mutations requiring constant vaccine updates that traditional methods cannot provide. Our platform addresses these urgent, unmet medical needs in a market where producers are desperate for solutions and willing to pay premium prices for effective protection.

Massive Market Opportunity with Clear Path to Potential Returns

The global swine industry represents a $60 billion market with enormous untapped potential for innovative solutions. With over 67,000 producers at risk in the US alone and 450 million commercial swine processed annually, our technology addresses a critical industry pain point that generates $23.4 billion in annual output. The European market adds another 263 million commercial swine and 117,000 at-risk producers, demonstrating the global scale of this opportunity. Our conservative target of just 15% global market penetration positions us for returns - a goal we believe is not only achievable but represents the kind of transformative market capture that could generational wealth for early investors. With producers desperate for solutions and a massive addressable market, we're positioned to deliver a potentially high-ROI opportunity sophisticated investors seek. Future projections are not guaranteed

This emphasizes the scale of opportunity while positioning the 15% target as both ambitious and achievable, creating excitement about the investment potential.

Kermode's Initial Market Focus

Kermode Biotechnologies uses AI to develop next-generation vaccines and antibody treatments protecting America's 85 million swine from deadly diseases like African Swine Fever, Senecavirus A, and Swine Influenza. Our innovative approach combines four vaccine technologies that can be stockpiled for rapid deployment during outbreaks. Our dual-strategy protocol enables immediate containment through antibody deployment in infected zones, followed by antigen vaccination in surrounding areas to prevent disease spread, safeguarding America's $23 billion swine industry.

Revenue Model

Kermode's revenue model operates on a dual-track approach addressing both preventive and emergency vaccination needs. For routine diseases like SIV and SVA, we target the annual vaccination market where farmers proactively protect their herds, generating steady recurring revenue. For ASFV, our model focuses on government stockpiling contracts and emergency response protocols, where rapid deployment of our dual-treatment system—antibodies for immediate containment followed by co-antigen vaccines for broader protection—commands premium pricing due to the critical nature of outbreak control. At $4-6 per treatment and targeting 15% market penetration, this approach yields significant revenue potential while addressing the most pressing threats to global swine health. The model scales efficiently from the US base market to global expansion, with stockpiling agreements providing predictable revenue streams independent of actual outbreak frequency.

Future projections are not guaranteed.

Use of Proceeds

This Wefunder raise is part of a larger $15M Series A round aimed at advancing Kermode Biotechnologies' AI-driven vaccine development pipeline. Funds will support completion of large-scale challenge studies for our swine disease vaccines, advance our ASFV antibody therapeutics through clinical trials, expand our manufacturing capabilities, and strengthen our intellectual property portfolio as we progress toward market entry.

Kermode Media

Current Technological Challenges Have Hindered Successful Treatment Options

Current swine virus vaccine approaches remain inadequate. ASFV vaccines fail due to the virus's complexity and safety concerns with attenuated strains, while SIV vaccines quickly become obsolete against rapidly evolving viral variants. SVA lacks any commercial vaccines entirely, forcing the industry to rely on biosecurity measures alone. These critical limitations demand innovative immunization technologies specifically tailored to each pathogen's unique challenges.

Solving Problems with Artificial Intelligence

Kermode Biotechnologies uses cutting-edge AI and breakthrough manufacturing to create safer, more effective immunotherapies at a fraction of traditional costs - delivering faster outcomes and higher returns for investors.

Viral Antigens Reimagined

Kermode is solving why most pig vaccines fail - and are creating a superior alternative that trains immune systems to become virus-destroying machines.

Where traditional vaccines use virus pieces that hide from the immune system, creating weak protection that fades quickly. We've redesigned these viral antigens, called toxoids, to be fully visible, forcing the immune system to build powerful, long-lasting antibodies that hunt and destroy viruses before infection occurs. Combined with a T-cell priming technology, we create a two-layer defense - 1. antibodies that neutralize viruses and 2. killer cells that eliminate infected cells.

The opportunity: This preventive approach protects herds months before outbreaks, targeting a $180 billion swine industry losing $3+ billion annually to viral diseases. We're selling immune system upgrades to an industry desperate for better protection than today's failing vaccines.

Antibody Design by Computational Learning

Kermode Biotechnologies delivers instant protection for pig farms when viral outbreaks strike. Our AI-designed antibodies provide immediate immunity - no waiting weeks for immunotherapies to work - and protect entire herds for up to 6 months with a single treatment.

The market opportunity is massive: Viral outbreaks can wipe out thousands of pigs in days, costing farmers millions and driving up pork prices globally. While traditional therapies take weeks to build immunity (often too late), our antibodies work instantly - like giving herds a pre-built immune system the moment disease threatens.

Why investors should pay attention: The global swine industry is worth over $180 billion annually, and producers desperately need rapid-response solutions. Our technology transforms crisis management into prevention, protecting both livestock and profit margins while positioning us in a growing animal health market that values speed and reliability above all else.

Robust Intellectual Property Portfolio Creates Defensible Market Position

Our innovation is protected by a comprehensive intellectual property strategy that establishes significant barriers to competition. We have filed 7 core patents covering our breakthrough technology's composition of matter, mechanism of action, and formulation methods, with 5 PCT conversions extending our protection globally. Our 20 national phase filings span key markets including the USA, Europe, China, and South-East Asia, ensuring market exclusivity through 2043. This top-rated, state-of-the-art IP portfolio, developed in partnership with Kohn & Associates PLLC, creates a defensible moat around our technology platform and provides investors with confidence that our competitive advantages are legally protected. With nearly two decades of patent protection remaining, early investors are positioned to benefit from sustained market exclusivity as we scale globally.